Guided Therapeutics, Inc. reported a significant increase in revenue for the fiscal year ending December 31, 2025, generating $766,948 compared to $6,940 in 2024. This growth was primarily driven by the sale of ten LuViva Advanced Cervical Scan devices and 49,031 RFID chips to customers in China. The cost of goods sold also rose to $195,797 from $4,574 in the previous year, reflecting the increased production and sales activity. Despite the revenue growth, the company reported a net loss attributable to common stockholders of $3.35 million, up from a loss of $2.59 million in 2024, largely due to increased operating expenses and interest costs.
The company has made strategic changes to its operations, including a focus on obtaining regulatory approvals for its products in key markets such as the United States and China. As of December 31, 2025, Guided Therapeutics had an accumulated deficit of approximately $157.1 million and negative working capital of $6 million. The company is actively pursuing FDA approval for LuViva, with a pivotal clinical trial completed in early 2026, and anticipates submitting the application to the FDA in the second quarter of 2026. Additionally, the company is working with distributors in Turkey and Indonesia to expand its market presence.
Operationally, Guided Therapeutics has faced challenges, including reliance on a limited number of distributors for sales and the need for additional capital to support its operations. As of December 31, 2025, the company had three employees and five consultants, indicating a lean operational structure. The company has also experienced difficulties in maintaining inventory levels, with a reserve of $818,000 for obsolete inventory. The total inventory was valued at $448,000, down from $633,000 in 2024, reflecting the company's efforts to manage costs amid fluctuating demand.
Looking ahead, Guided Therapeutics aims to increase its revenue through strategic partnerships and regulatory approvals. The company expects potential sales of approximately $1 million within the next twelve months, contingent on regulatory outcomes and market conditions. However, the company acknowledges the uncertainty surrounding its ability to raise additional funds, which is critical for sustaining operations and achieving profitability. The ongoing geopolitical tensions, particularly related to the conflict in Ukraine, may also impact the company's operations and market access in certain regions.
About GUIDED THERAPEUTICS INC
Guided Therapeutics, Inc. develops innovative medical devices focused on non-invasive cancer detection, primarily through the LuViva Advanced Cervical Scan. The device uses biophotonics technology to identify cervical cancers and precancers painlessly at the point of care. The company targets global markets, including developing countries and developed nations, emphasizing regulatory approval, strategic partnerships, and international distribution to improve early cancer detection and reduce healthcare costs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.